HIGH PLASMA-LEVELS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN POLYCYTHEMIA-VERA AND ESSENTIAL THROMBOCYTHEMIA ARE ASSOCIATED WITH THROMBOSIS

被引:24
作者
CANCELAS, JA [1 ]
GARCIAAVELLO, A [1 ]
GARCIAFRADE, LJ [1 ]
机构
[1] HOSP RAMON Y CAJAL, DEPT HEMATOL, E-28034 MADRID, SPAIN
关键词
PLASMINOGEN ACTIVATOR INHIBITOR; POLYCYTHEMIA VERA; ESSENTIAL THROMBOCYTHEMIA; HYPERCOAGULABILITY;
D O I
10.1016/0049-3848(94)90226-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We attempted to determine if a hypercoagulability state exists in patients with polycythemia vera (PV) and essential thrombocythemia (ET). We studied the hematocrit level, platelet count, use of any antiaggregant drugs, thrombotic or bleeding accidents and plasma levels of antithrombin III, protein C, total protein S, free protein S, vWF:Ag (Von Willebrand's factor related antigen), thrombin-antithrombin complexes, D-dimer, fibrinolytic activity, tissue plasminogen activator, plasminogen and PAI-1 in 33 patients (19 with ET and 14 with PV). PAI-1 plasma concentration was significantly higher in, both ET and PV patients than in the control group, and were higher in those patients with previous thrombotic episodes than in asymptomatic patients or with previous bleeding episodes. Increasing age was associated to more thrombotic episodes while younger patients presented with more hemorrhagic complications. A linear correlation between platelet count and PAI-1 levels in PV patients (r=0.44, p<0.05) and ET patients (r=0.30, p<0.05) was found. Fibrinolytic activity in patients with ET was significantly decreased when compared to the control group. A hypofibrinolytic state could be an additional factor which could be used as a predictive index of the thrombotic or bleeding tendency in each patient.
引用
收藏
页码:513 / 520
页数:8
相关论文
共 28 条
[1]   ANTITHROMBIN (HEPARIN COFACTOR) ASSAY WITH NEW CHROMOGENIC SUBSTRATES (S-2238 AND CHROMOZYM-TH) [J].
ABILDGAARD, U ;
LIE, M ;
ODEGARD, OR .
THROMBOSIS RESEARCH, 1977, 11 (04) :549-553
[2]  
BAKER RI, 1988, EUR J HAEMATOL, V40, P267
[3]   THROMBOHEMORRHAGIC COMPLICATIONS IN 101 CASES OF MYELOPROLIFERATIVE DISORDERS - RELATIONSHIP TO PLATELET NUMBER AND FUNCTION [J].
BARBUI, T ;
CORTELAZZO, S ;
VIERO, P ;
BASSAN, R ;
DINI, E ;
SEMERARO, N .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (11) :1593-1599
[4]  
BONEU B, 1980, SCAND J HAEMATOL, V25, P214
[5]   THE INCIDENCE OF THROMBOTIC AND HEMORRHAGIC DISORDERS IN ASSOCIATION WITH EXTREME THROMBOCYTOSIS - AN ANALYSIS OF 129 CASES [J].
BUSS, DH ;
STUART, JJ ;
LIPSCOMB, GE .
AMERICAN JOURNAL OF HEMATOLOGY, 1985, 20 (04) :365-372
[6]   EVIDENCE FOR A RAPID INHIBITOR TO TISSUE PLASMINOGEN-ACTIVATOR IN PLASMA [J].
CHMIELEWSKA, J ;
RANBY, M ;
WIMAN, B .
THROMBOSIS RESEARCH, 1983, 31 (03) :427-436
[7]   INCIDENCE AND RISK-FACTORS FOR THROMBOTIC COMPLICATIONS IN A HISTORICAL COHORT OF 100 PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA [J].
CORTELAZZO, S ;
VIERO, P ;
FINAZZI, G ;
DEMILIO, A ;
RODEGHIERO, F ;
BARBUI, T .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :556-562
[8]  
DECLERCK PJ, 1988, BLOOD, V71, P220
[9]   INDUCTION OF PLASMINOGEN-ACTIVATOR INHIBITOR BY PRODUCTS RELEASED FROM PLATELETS [J].
FUJII, S ;
SOBEL, BE .
CIRCULATION, 1990, 82 (04) :1485-1493
[10]   DOSE-RESPONSE CURVES IN FIBRIN PLATE ASSAY - FIBRINOLYTIC-ACTIVITY OF PROTEASES [J].
HAVERKATE, F ;
TRAAS, DW .
THROMBOSIS ET DIATHESIS HAEMORRHAGICA, 1974, 32 (2-3) :356-365